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Introduction: A challenge of cancer therapy is to optimize thera-
peutical options to individual patients. Cancers with similar histol-
ogy may show dramatically different responses to therapy, indicat-
ing that a refined approach needs to be developed to classify tumors
by intrinsic characteristics that may predict response to chemother-
apy. Global expression profile-based classification has the potential
to identify such tumor-intrinsic subclasses. Pemetrexed effective-
ness has been related to the expression of its target thymidylate
synthase. The relatively frequent resistance of squamous cell carci-
noma to Pemetrexed is correlated with high levels of thymidylate
synthase expression.
Methods: A global expression profile-based molecular classification
of non-small cell lung cancer (NSCLC) was performed. Gene
expression was used to predict Pemetrexed responsiveness. The
distinct molecular attributes of NSCLCs predicted likely to be
resistant to Pemetrexed were bioinformatically characterized. We
tested if routine immunohistochemical markers can be used to
distinguish putative Pemetrexed responders, predicted by gene sig-
natures, from nonresponders.
Results: Ninety NSCLCs were divided into six subclasses by gene
expression signatures. The relevance of this novel phenotyping was
linked to other tumor characteristics. Two of the subclasses corre-
lated to putative Pemetrexed resistance. In addition, the identified
signature genes characterizing putative Pemetrexed responsiveness
predicted therapeutic benefit in a subset of squamous cell carcinoma.
Conclusions: Gene expression signatures can be used to identify
NSCLC subgroups and have potential to predict resistance to Pem-
etrexed therapy. We suggest that a combination of classical patho-
logical markers can be used to identify molecular tumor subclasses
associated with predicted Pemetrexed response.
Key Words: Carcinoma, Non-small-cell lung cancer, Expression
profiling, Pemetrexed.
(J Thorac Oncol. 2012;7: 105–114)
Currently, non-small cell lung cancer (NSCLC) is classi-fied based on microscopic analysis of specific histolog-
ical features, resulting in morphological subtyping and grad-
ing. This histopathological classification correlates poorly
with patient prognosis and clinical outcome. Alternatively,
genome-wide expression studies have revealed that NSCLCs
may be classified beyond classical histopathological criteria,
and the resultant subgroups might better indicate the diver-
gence of tumor progression and recurrence.1–4 However, the
clinical potential of such refined grouping of NSCLCs needs
further exploration.
Pemetrexed is one of the most effective drugs for the
treatment of NSCLC. Pemetrexed is a folate antimetabolite
and targets multiple enzymes essential for nucleotide biosyn-
thesis.5 It was established that it has possibly superior activity
compared with commonly used agents for treatment of ade-
nocarcinoma (ADC) and large-cell carcinoma (LCC) but is
thought to be less effective for the treatment of squamous cell
carcinoma (SCC). By using real-time-polymerase chain reac-
tion, a study identified that the efficacy of Pemetrexed treat-
ment was related to messenger RNA (mRNA) expression
level of thymidylate synthase (TYMS), a key molecule in the
thymidine synthesis pathway.6 It was also demonstrated that
high expression of TYMS is associated with resistance to
Pemetrexed in NSCLC (p  0.006). Furthermore, a higher
expression of TYMS is more often seen in SCC than in ADC
and LCC.7–9 On the basis of those observations, Pemetrexed
was approved as first-line treatment for advanced non-SCC
NSCLC patients.8
Among ADC and LCC patients, the response rate to
Pemetrexed varies between 28 and 61%.10–12 Intriguingly, a
significant number of ADC and LCC cases with high level of
TYMS mRNA expression were observed,13,14 suggesting that
Pemetrexed treatment would not be effective in those cases.
It also indicates that to reach a higher response rate for
Pemetrexed treatment, it is vital to improve the criteria for
personalized patient selection. Determination of TYMS ex-
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pression levels by immunohistochemistry (IHC) lacks the
sensitivity required for this purpose.14
In this study, we show that early-stage NSCLCs can be
partitioned into six subgroups based on global gene expres-
sion profiles. In particular, a subset of ADC and LCC was
clustered in a novel subgroup. The potential clinical rele-
vance of these novel groups was explored by linking this
refined phenotyping to the predicted sensitivity to Pem-
etrexed. Analysis of the expression levels of relevant genes
predicted that tumors in this novel subgroup are highly likely
to be resistant to Pemetrexed therapy. Conversely, a subset of
SCCs are putative responders (Rs) to Pemetrexed treatment.
The identification of these distinct subgroups of NSCLC
suggests that biological characteristics assessed by gene ex-
pression profiling may aid in reliably stratifying patients with
respect to the choice of therapeutic agents.
MATERIALS AND METHODS
NSCLC Tumor Samples and Validation
Microarray Data Sets
Ninety resected tumor samples from NSCLC patients
were collected and studied under an anonymous tissue pro-
tocol approved by the medical ethical committee of Erasmus
University Medical Center.15 Microarray data are available at
the Gene Expression Omnibus of the National Center for
Biotechnology Information (GSE19188). Patient and tumor
characteristics are summarized in Supplemental Table 1 (Sup-
plemental Digital Content 1, http://links.lww.com/JTO/A168).
Two additional NSCLC microarray datasets, one containing 25
NSCLC cell lines and the other 96 primary NSCLC cases from
Duke University, were obtained from the Gene Expression
Omnibus database (GSE8332 and GSE3593). The sensitivity
of NSCLC cell lines to Pemetrexed was previously tested,16
and IC50 response data were downloaded from the DTP
website (http://dtp.nci.nih.gov).
Microarray Data Analysis
Microarray preparation and microarray data process-
ing and normalization are as described in Ref. 15 and in
Supplementary Methods (Supplemental Digital Content 2,
http://links.lww.com/JTO/A169).
Unsupervised Clustering and Visualization of
Gene/Sample Similarity
This was performed as described in Ref. 15 and in
Supplementary Methods (Supplemental Digital Content 2,
http://links.lww.com/JTO/A169).
Scoring Formula Using Internal Reference
Genes
The detailed methodology of the predictive algorithm is
described in Supplementary Methods (Supplemental Digital
Content 2, http://links.lww.com/JTO/A169). The scheme pre-
dicts tumor response using the expression difference between
Pemetrexed targets and the Internal Reference Genes, which
is based on the average expression level of 11 selected probe
sets. NSCLC patients were stratified in such a way that
approximately 60% of cases were supposed to respond to
Pemetrexed, while the remaining approximately 40% of cases
with higher expression levels of the signature genes were
deemed to be nonresponders (NRs).
Supervised Analysis to Identify Pemetrexed
Resistance-Associated Genes
Gene profiling with respect to predicted sensitivity to
Pemetrexed was performed using Significance Analysis of
Microarray.17 Significance Analysis of Microarray discov-
ered differentially expressed genes between two classes,17
e.g., predicted NRs and Rs.
The obtained signatures were subjected to identify
subgroups of genes that maintain the capacity of the complete
signatures in distinguishing different groups optimally.18 The
performance of minimized signatures was validated by
“leave-one-out” cross validation.19 Optimized gene signa-
tures characterized a certain tumor property, such as belong-
ing to a novel subgroup or putative resistance to Pemetrexed
treatment.
Pathway Enrichment Analysis
Functional pathways overrepresented by each signature
were identified using different methodologies, and the com-
mon ones were used to extract molecular characteristics
driving the novel grouping or predicted differential sensitivity
to Pemetrexed (Supplemental Methods and Results, Supple-
mental Digital Content 2, http://links.lww.com/JTO/A169).
Signature genes were mapped to public databases of
functionally related gene sets, Gene Ontology and Kyoto
Encyclopedia of Genes and Genomes. Alternatively, a global
gene set enrichment analysis was performed using expression
of all informative genes on the microarrays.20
The enrichment of certain gene sets was statistically
determined (enrichment p value 0.05) by comparing the
co-occurrence of gene members associated with a certain
function in the generated gene list to that in a reference
background of the human genome.
In addition, the relationships between the identified gene
sets were explored. The related gene sets were hierarchically
linked on the basis of interrelationships in a network context.
Subordinate gene sets were combined to ancestors because of
the inheritance of genes in a hierarchical ontologism.
Tissue Microarray Analysis/IHC
Routine IHC was performed as previously described.15
Tissue microarrays (TMAs) containing 0.6 mm cores of
formalin-fixed paraffin-embedded tumors were used. The
TMA is composed of 68 of the 90 tumor tissues and 2 normal
lung tissues, in 3 replicates, from the Erasmus MC patient
cohort used for the expression microarray analyses. TMA
blocks were cut into 6-m slices, and antigen retrieval was
performed by a 20-minute incubation at 95°C using Tris-
ethylenediaminetetraacetic acid buffer (Klinipath, Duiven,
The Netherlands). Slides were cooled down to room temperature
and stained with the primary antihuman antibodies (TYMS,
epidermal growth factor receptor [EGFR], tumor protein p53
[TP53], TP63, thyroid transcription factor 1 [TTF1], SYG,
neural cell adhesion molecule 1 [NCAM1], chromogranin A
[CHGA], or KRT5). The sources of the antibodies and dilutions
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used are listed in Supplemental Table 8 (Supplemental Digital
Content 1, http://links.lww.com/JTO/A168).
A secondary step was incubated for 30 minutes with
rabbit anti-mouse 1:50 (Z0259 Dako, Glostrup, Denmark)
followed by 1:50 diluted alkaline phosphatase anti-alkaline
phosphatase method (D0651 Dako). Staining was visualized
using 20-minute development with New Fuchsine substrate.
TMA evaluation and protein staining quantification were
performed double blinded by a lung pathologist (M.A.d.B.).
The intensity of protein staining was classified using a four-
grade scale: with 0 indicating fewer than 10% of positive cells,
1 for 10 to 25%, 2 for 25 to 50%, and 3 greater than 50%.
RESULTS
Classification of NSCLC in Six Subgroups
Unsupervised clustering of expression profiles revealed
six subclasses within the 90 Erasmus MC NSCLC cases. The
clustering was based on the similarity in global gene expres-
sion between the NSCLC samples, and the six distinct sub-
groups were recognized using 4791 informative probe sets
(Figure 1). All tumor samples were clustered into six groups.
Two of these groups correlated well with classical histopa-
thology: group3 (G3) displayed a dominant SCC contribu-
tion, while the carcinoid (CAR) samples (n  4) were
exclusively assigned to group5 (G5). By contrast, other
groups showed a weak association with classical histology.
They were to varying degrees composed of mixed histopatho-
logical NSCLC. The four non-SCCs in G3 were undistin-
guishable by expression profiles from the other SCCs in G3,
with well-known SCC markers, including TP63, KRTs, and
SERPINB, uniformly high expressed. Additional pathologi-
cal analysis revealed that two of them presented either posi-
tive staining for TP63 or apparent squamous cell elements.
We found that group 4 (G4), G5, and group 6 (G6)
comprised neuroendocrine NSCLC, including large-cell neu-
roendocrine carcinoma (LCNEC), CAR, and NSCLC with neu-
roendocrine features, mainly of the ADC histological subtype.
Most LCC and LCNEC cases were mingled with ADC in G4
and G6. All CARs were clustered into an independent group
(G5). Although the expression profiles of CAR showed to some
extent similarity to G4 and G6, the observation that CAR displayed
a unique transcriptome profile suggested that CAR is a group of
NSCLC with distinct behavior with respect to tumor cell aggres-
siveness, tumor response to therapy, and prognosis.4,21–23
Compared with group 1 (G1) and group 2 (G2), ADC in
G4 and G6 displayed gene expression patterns suggestive of
neuroendocrine features. Regardless of histological consis-
tency between G1 and G2, the NSCLCs in these two groups
were distinguished by a low degree of cell differentiation in
G1 and the expression of a large number of immune-related
genes in G2. This suggested that these two groups might
display a different natural course of disease.
Gene signatures that reflect patterns of gene and path-
way deregulation, distinguishing these six subclasses, were
bioinformatically identified (Supplementary Results, Supple-
mental Digital Content 2, http://links.lww.com/JTO/A169)
(Supplemental Tables 2 and 3, Supplemental Digital Content
1, http://links.lww.com/JTO/A168).
Gene Expression-Based Prediction of Response
to Pemetrexed
The sensitivity of tumors to Pemetrexed treatment is
thought to be negatively correlated with the expression levels of
the enzymes in the nucleotide metabolic pathways.9,24 Expres-
sion of the relevant genes was extracted from the microarray
data, and these were subsequently used to develop predictive
schemes for Pemetrexed responsiveness. According to the In-
ternal Reference Genes scheme, of 90 NSCLC patients, 35%
were predicted as NR and 52% were predicted to be R. The
remaining cases were predicted with intermediate response to
Pemetrexed. The relative expression of TYMS in predicted NRs
is 177.1 (95% confidence interval [CI]: 143.2–210.9), 8.2-fold
higher than that in normal lung tissues; while predicted Rs
displayed a 2.2-fold increase in relative expression of TYMS
compared with normal lungs. When expression of dihydrofolate
reductase and phosphoribosylglycinamide formyltransferase was
included in the predictive scheme, a similar output was observed.
The differential activity of relevant pathways in NR
and R determined by a global analysis is shown in Sup-
plemental Figure 1 (Supplemental Digital Content 3,
http://links.lww.com/JTO/A170). In addition, a set of 426
probe sets (346 genes) characterizing putative NRs was
identified using supervised analysis. Surfactant genes, SOX7,
SLC16A4, and SLC46A3, were down-regulated in predicted
NRs. The bioinformatics analysis revealed that signature
genes were functionally enriched in gene sets for cell cycle
regulatory functions, such as E2Fs, cyclins, and CDCs; cell
division functions such as GTSE1, KIFs, MCMs, and
IGFBPL1; cell growth and invasion including MMP19; and
oncogenes and tumor suppressor genes such as MYB, NBL1,
and RAS. As expected, other functional pathways included
pyrimidine and purine metabolism and folate biosynthesis
(Supplemental Table 4, Supplemental Digital Content 1,
http://links.lww.com/JTO/A168). A subset of this signature,
represented by 25 probe sets, performed optimally in predict-
ing Pemetrexed response (Supplemental Table 5, Supplemen-
tal Digital Content 1, http://links.lww.com/JTO/A168).18,19
Correlation of Putative NSCLC Responsiveness
to Other Tumor Characteristics
Next, the predicted Pemetrexed resistance profile was
studied in relation to NSCLC histology. The histological
subtype (ADC, SCC, or LCC) was assigned using the histol-
ogy signature identified previously.15 Within the three major
subtypes, LCC contained the highest expression of TYMS
(192.0; 95% CI: 125.6–258.4), followed by SCC (86.6; 95%
CI: 73.0–100.1) and ADC (76.1; 95% CI: 58.5–93.7; Figure
2A). A significant difference in TYMS expression was ob-
served between each subtype of NSCLC and noncancerous
tissues, with 8.85-, 4-, and 3.5-fold increases in LCC, SCC,
and ADC, respectively. The difference in TYMS expression
was statistically significant between LCC and the other two
subtypes, ADC (p  0.002) and SCC (p  0.004), but not
between ADC and SCC (p  0.39). Predicted resistance to
Pemetrexed was found in 27% of ADC, 33% of SCC, and
53% of LCC. In contrast, all healthy lung tissue samples (n
65) except for one were stratified as sensitive to Pemetrexed.
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A Novel NSCLC Group Is Associated with
Predicted Pemetrexed Resistance
Because in our cohort predicted Pemetrexed-resistant
cases were not significantly overrepresented in any of the
histological subtypes, we correlated predicted Pemetrexed
responsiveness to the six molecularly defined subgroups. In
four of the six groups, fewer than 25% of the cases were
defined as NRs, with percentages of 20%, 0%, 0%, and 25%
in G1, G2, G5, and G6, respectively. Approximately 32%
cases from G3, which were characterized by SCC, were
FIGURE 1. Identification of six subgroups in the Erasmus MC NSCLC cohort. Six subgroups are indicated by G1 to G6. A,
Correlation view of gene expression in the 90 Erasmus MC NSCLC samples. Pairwise correlations between any two samples
are displayed. The colors of the cells represent Pearson’s correlation coefficient values between any two samples, with deeper
red indicating higher positive and deeper blue lower negative correlations. The red diagonal line displays the self-to-self com-
parison of each sample. B, Relative expression levels of TYMS, cell proliferation genes, and neuroendocrine genes are shown
for each of the six identified NSCLC subgroups. Boxes show the distribution of gene expression in each subgroup, with dots
representing outliers. The dashed line shows the median expression of that gene across all NSCLC samples. NSCLC, non-small
cell lung cancer; G1, group1; G6, group6; TYMS, thymidylate synthase.
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predicted as NRs. In contrast, a remarkable proportion (94%,
17/18) of NRs predicted by the 25 probe set signature was
observed in G4 (Figure 3A). We conclude that tumors in G3
(32% of SCC) and in particular G4 have the highest proba-
bility to be classified as NR.
The expression profile of G4 was distinguishable from
other neuroendocrine tumors. A differential overexpression
of neuroendocrine markers, including ASCL1, DDC, and
MAST4, was observed among neuroendocrine groups, with a
two- to fourfold difference between G4 and G6. In contrast,
FIGURE 3. Predicted Pemetrexed sensitivity in NSCLC sub-
groups and NSCLC cell lines. A, NSCLC cases predicted to
be resistant (NR) or sensitive (R) to Pemetrexed are corre-
lated to expression profiling-based subgroups (G1 to G6). B,
Validation of Pemetrexed resistance signature using NSCLC
cell lines. Predicted sensitivity to Pemetrexed for NSCLC cell
lines is compared with experimentally established sensitivity.
For each cell line, data from two independent microarrays
were used (number of cases). C, Performance of the Pem-
etrexed-resistance prediction signature on the Duke
NSCLC Cohort. The 96 primary NSCLC cases were classi-
fied into subgroups using the group signature genes (indi-
cated by G1 to G6). The predicted response to Pem-
etrexed by the 25-probe set resistance signature and its
correlation to the subgroups are displayed. NSCLC, non-
small cell lung cancer; NR, nonresponder; R, responder;
G1, group1; G6, group6.
FIGURE 2. Relative expression of TYMS in relation to classi-
cal NSCLC histology. Relative expression levels of TYMS in
histology signature-assigned NSCLC groups.15 A, Erasmus
MC cohort and (B) Duke Cohort. Boxes show the distribu-
tion of TYMS expression in each subgroup with crosses rep-
resenting outliers. The band in the box shows the median
expression of TYMS in that group. TYMS, thymidylate syn-
thase; NSCLC, non-small cell lung cancer.
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MCM6, TYMS, and CDCA7 showed a relatively higher
expression in G4 compared with G6 (Figure 1B).
Pemetrexed is transported in and out of cells by mem-
brane proteins such as folate receptor 1 (FOLR1), SLC19A1,
and ATP-binding cassette family members. Moreover, Pem-
etrexed is metabolized by folylpolyglutamate synthetase. The
aberrant expression of such molecules may also contribute to
Pemetrexed resistance. We observed a lower expression of
FOLR1 and a higher expression of ATP-binding cassette,
subfamily C (CFTR/MRP), member 1 in G4 compared with
either other groups or other neuroendocrine tumors (p values
0.015 and  0.038).
Bioinformatics analysis revealed that pyrimidine me-
tabolism and epidermal growth factor signaling pathways
were more activated in G4 compared with other
NSCLCs (Supplemental Figs. 4 and 5, Supplemental Dig-
ital Content 6 and 7, http://links.lww.com/JTO/A174 and
http://links.lww.com/JTO/A175). Moreover, in comparison
to other neuroendocrine tumors, such as G6, pyrimidine
metabolism was also more up-regulated, while the histidine
pathway was more down-regulated in G4 (Figure S6). We
conclude that the newly identified G4 of NSCLC has distinct
molecular characteristics associated with predicted Pem-
etrexed resistance.
Validation of the Putative Pemetrexed
Responsiveness Signature
The expression of resistance-associated genes identi-
fied with primary NSCLCs was validated in two independent
sample cohorts, in transcriptionally profiled NSCLC cell lines
(GSE8332) and primary NSCLCs (GSE3141/Duke Cohort).
The performance of our signature was evaluated by compar-
ing the predicted Pemetrexed sensitivity of the cell lines to
the measured response in drug sensitivity assays (Figure
3B).16 In addition, the sensitivity to Pemetrexed was pre-
dicted for primary NSCLCs in the Duke Cohort (Figure 3C).
The 25-probe set signature correctly predicted response to
Pemetrexed in 92% (23/25) of the cell lines. Resistant cell
lines were all correctly predicted; the sensitivity of predicting
resistance was 100% and specificity 93% (Figure 3B).
TYMS Expression as a Predictor of Pemetrexed
Response
TYMS expression has been associated with Pemetrexed
efficacy previously.6 TYMS is one of the 25 genes in our
Pemetrexed response prediction signature. Therefore, we
tested if TYMS expression alone could be used as a predictor
for Pemetrexed sensitivity. In the Erasmus MC cohort,
TYMS expression correlated significantly with gene signa-
ture-predicted Pemetrexed sensitivity (p 0.0001, 2 test). In
NSCLC cell lines, TYMS expression was not related to the
observed sensitivity to Pemetrexed treatment (p  0.482, 2
test). We conclude that the Pemetrexed responsiveness is
determined by more genes than TYMS alone, illustrating the
value of the extended 25-gene Pemetrexed response predic-
tion signature that we developed.
Measurement of TYMS Expression in NSCLC
by TMAs
TYMS protein staining was performed using TMAs of
NSCLC samples (n 68) that were used for the microarrays.
Staining of the TMAs was graded from scale 0 to 3. The
mRNA expression level for each staining category is shown
in Supplemental Figure 2 (Supplemental Digital Content 4,
http://links.lww.com/JTO/A171). As only one sample was
graded 3, it was combined with the grade 2 NSCLCs. The
mRNA expression of TYMS of grade 2 was 3.73-fold and
2.52-fold higher than grade 0 and grade 1 (p value  1.11E-7).
The correlation between staining intensity and predicted Pem-
etrexed resistance is shown in sSpplemental Figure 2 (Supple-
mental Digital Content 4, http://links.lww.com/JTO/A171).
Over 87.5% grade 2 NSCLCs were predicted NR to Pem-
etrexed. Conversely, 33.5% of grade 1 NSCLC and 19.4%
grade 0 were predicted NRs. The expression of TYMS in NR
between grade 0 and grade 1 was not significantly different (p
value  0.993). When the TYMS antibody was more diluted
(1:50), over 85% (6/7) grade 2 samples were predicted NR,
similar to the results of TMA at titer 1:10. Eight samples had
moderate staining (grade 1), of which two samples were
predicted NR (25%). The TYMS expression was not detected
with TMA at titer 1:50 in the rest of the samples (n  53,
78%), illustrating the current limitations of TYMS IHC for
assessing Pemetrexed responsiveness, in agreement with pre-
vious work.14,25
We conclude that very high protein expression of TYMS
determined by IHC correlates well with TYMS mRNA expres-
sion, while low protein expression of TYMS on the TMA
correlates poorly with TYMS mRNA expression.
Potential for Practical Application
Next, we investigated whether (a combination of) rou-
tine histopathological markers could be used to stratify the
putative Pemetrexed Rs/NRs. We used eight well-known
histopathological markers, including KRT5, EGFR, TTF1,
TP53, and neuroendocrine markers. The expression of any of
these markers failed to stratify patients into the predicted
groups with differential sensitivity. Furthermore, stratifica-
tion by any of these routine histopathological markers also
failed when it was performed with the prior knowledge of the
classical histology or pathological stage (Supplemental Fig. 3,
Supplemental Digital Content 5, http://links.lww.com/JTO/A172)
(Supplemental Table 6, Supplemental Digital Content 1,
http://links.lww.com/JTO/A168). However, when the strati-
fication was interpreted with the knowledge of novel group-
ing and the expression of routine histopathological markers
was used cooperatively, putative Pemetrexed sensitive and
resistant cases could be distinguished, with the best perfor-
mance in G3 and still some exceptions in G4 and G6 (Figure
4). Fourteen out of 17 predicted Rs in G3 can be identified by
a combination of staining for TP53 and EGFR. The expres-
sion of neuroendocrine markers was observed in Rs from G1
(n  2) and G5 (n  4), and both NR (n  1) and R (n  1)
from G6. There were four cases in G4 for which TMA
staining was inconclusive because it failed for one or all
markers. We conclude that the cooperative use of routine
Hou et al. Journal of Thoracic Oncology • Volume 7, Number 1, January 2012
Copyright © 2011 by the International Association for the Study of Lung Cancer110
histological markers and molecular classification can be used
to predict the sensitivity of a subset of NSCLC to Pem-
etrexed.
DISCUSSION
Currently, the administration of chemotherapy in
NSCLC patients is based on histology, and the response rates
to treatment are approximately 16% for single agents and
approximately 40% for combined regimens.26 The fact that
cancer patients with similar histopathological features re-
spond dramatically different to the same therapeutic agent
indicates that histology alone is insufficient to predict the
response to therapeutics. Ideally, therapeutic regimens should
be tailored for individual patients to obtain maximal antitu-
mor effects. For example, EGFR tyrosine kinase inhibitor
treatment in ADC patients improved the response rate to
approximately 68%, but EGFR tyrosine kinase inhibitor in
non-ADC patients harboring active EGFR mutations is less
effective,27,28 illustrating the importance of better defining the
target group by molecular analysis. Despite this promising
example, tailored therapy for NSCLC remains largely elu-
sive. Most NSCLCs of similar histology and grade receive
the same therapy, and differences in molecular characteristics
are not taken into account routinely. It is therefore important
to develop algorithms for molecular identification of patients
who would be sensitive or resistant to a specific therapy.
The folate antimetabolite Pemetrexed is a promising
agent for the treatment of NSCLC. Currently, the adminis-
tration of Pemetrexed is directed by classical histological
criteria.10 In this study, we present an approach to implement
tailored Pemetrexed therapy in NSCLC. It is based on the use
of gene expression profiles to systematically assess the pre-
dicted response to Pemetrexed.
Subgrouping of NSCLC Implies Common
Molecular Characteristics of NSCLC Subtypes
Gene expression profiling can be used to reveal tumor
features that are relevant to clinical outcome. For example,
clustering of ADC or SCC cases based on gene expression
profiles identified subgroups presenting favorite overall sur-
vival.2,3,29–31 Microarray-derived gene signatures have also
demonstrated the ability to define the risk of NSCLC recur-
rence.32 Ultimately, molecular profiling would be expected to
predict the response to specific therapies. In breast cancer cell
lines, gene signatures were identified that reflect the activa-
tion status of oncogenic pathways. On the basis of these
signatures, the coordinated active status of pathways was
obtained that not only defined prognosis in specific patient
subgroups but also predicted the sensitivity to therapeutic
agents targeting key components of these pathways.33 In this
study, we classified NSCLCs into six groups, independent of
classical histopathology, using microarray-based molecular
profiles. Tumors clustered in the same subgroups present
similar patterns of gene expression and pathway deregulation
despite often variable histopathology (Supplemental Fig. 4, Supple-
mental Digital Content 6, http://links.lww.com/JTO/A173)
(Supplemental Fig. 5, Supplemental Digital Content 7,
http://links.lww.com/JTO/A174). For example, tumors clus-
tered in G4 are histologically different—ADC or LCC. But
they are molecularly similar, with deregulation of the tyrosine
metabolism pathway and expression of the neuroendocrine
markers.
Moreover, G6 tumors are also histologically ADC or
LCC but molecularly characterized by altered histidine me-
tabolism (Supplemental Fig. 6, Supplemental Digital Content
8, http://links.lww.com/JTO/A176). Importantly, the group
FIGURE 4. Utility of routine IHC
markers to identify putative NR and
R to Pemetrexed therapy. The ex-
pression of eight IHC markers in 68
of 90 NSCLC and two normal lung
tissues (G0) was detected by TMA
and used for cluster analysis. High
staining is shown in red and low
staining is shown in green. Failed
IHC staining is shown in purple.
NSCLC cases are annotated with
predominantly present expression
profile-assigned subgroup(s) (G1 to
G6) on the right and predicted
Pemetrexed responsiveness (resis-
tant case [NR]: gray; sensitive case
[R]: orange) on the left. IHC, im-
munohistochemistry; NR, nonre-
sponder; R, responder; NSCLC,
non-small cell lung cancer.
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signature defined five subgroups of similar size and compo-
sition in the independent Duke NSCLC Cohort (Figure 3C)
(Supplemental Table 7, Supplemental Digital Content 1,
http://links.lww.com/JTO/A168). G5/CAR was absent be-
cause this tumor type was not represented in the Duke
Cohort. This strongly supports the notion that at least five
common subtypes of NSCLC exist and that these can be
classified by oncogenomics. This molecular classification
might be used to further refine conventional histopathology in
depicting tumor biology and revealing the underlying onco-
genic phenotypes. The identification of these distinct NSCLC
groups provides an opportunity to explore molecular classi-
fication as a tool to tailor the therapeutic regimens for
individual NSCLC patients. We have applied this to predict
Pemetrexed response in NSCLC cases.
Molecular Characteristics of NSCLC Associated
with Putative Sensitivity to Pemetrexed
Treatment
We did not observe a significant difference in patient
characteristics, such as gender, age, or smoking habit, nor
postoperation survival among the six subgroups. This is
supported by the fact that the group signature does not
show overlap with our previously determined survival
signature.15 However, distinct patterns of oncogenic path-
way deregulation in each group suggest that the response
to a particular pharmacological treatment might differ
between the NSCLC subgroups (Supplemental Table 2,
Figs. 4 and 5, Supplemental Digital Content 1, 6, and 7,
http://links.lww.com/JTO/A168, http://links.lww.com/JTO/A173,
and http://links.lww.com/JTO/A174).We found that the
TYMS expression-based predictions of Pemetrexed response
did not correlate well with classical histology, challenging the
current guideline to limit its use to ADC and LCC cases. We
identified a group of NSCLC (G4), composed mainly of ADC
and LCC cases, in which a large proportion of tumors are
predicted to be resistant to Pemetrexed. In contrast, ADC and
LCC cases classified in G1 and G6 were identified as candi-
dates for Pemetrexed therapy as they were predicted to
respond favorably (Figure 3).
According to previous clinical trials, LCC patients
showed the best response to Pemetrexed.11 This is contradic-
tory to the predicted response in the Erasmus MC cohort.
This paradox may result from the difficulty in distinguishing
LCC from other types of NSCLC. The classification of LCC
by routine pathology is prone to considerable interobserver
variation, for instance 62.5% of LCC cases in our previous
study were differentially classified between two pathologists.15
A refined classification of LCC is possible with the use of
additional IHC markers which are not routinely used, as exem-
plified by our TMA results (Supplemental Table 6, Supplemen-
tal Digital Content 1, http://links.lww.com/JTO/A168).
In this study, NSCLCs were histologically classified
with the aid of a 75-gene histology signature identified in our
previous study, resulting in molecularly defined NSCLC
subtypes sharing a distinct gene expression profile.15 Addi-
tional IHC showed that at least one of three LCC markers
(NCAM1, CHGA, or synaptophysin) was expressed in 59% of
the gene signature-assigned LCC samples, compared with only
7.5% in the remaining samples (Supplemental Table 6, Supple-
mental Digital Content 1, http://links.lww.com/JTO/A168).
Remarkably, approximately 68% of SCC in our cohort
and 47% of SCC in the Duke Cohort were predicted to be
sensitive to Pemetrexed therapy. The molecular differences
between SCC NR and R were similar to those between
non-SCC NR and R. The expression of FOLR1 is lower in
both SCC NR and non-SCC NR, while ATP-binding cassette,
subfamily C (CFTR/MRP), member 1 and TP53 are overex-
pressed in the same patients (Supplemental Table 6, Supple-
mental Digital Content 1, http://links.lww.com/JTO/A168)
(Supplemental Fig. 7, Supplemental Digital Content 9,
http://links.lww.com/JTO/A177). Pyrimidine and purine me-
tabolism were activated at a higher level in NRs compared
with R. This indicates that Pemetrexed may be an effective
therapeutic agent for a subset of SCC patients identified by
this approach. This observation is supported by a phase III
study in which no significant association between advantage
of Pemetrexed treatment and histological subtype was ob-
served.34 In a recently published meta-study by Scagliotti et
al., differential efficacy of Pemetrexed by NSCLC histology
was evaluated in three large Phase III trials. Although re-
sponse rate to Pemetrexed in SCC patients was inferior to that
in non-SCC patients, a subset of SCC patients (23.4%, com-
pared with 28.6% in non-SCC) sensitive to Pemetrexed
therapy was observed.35
Chemotherapy is not a standard of care for patients with
pulmonary CAR tumors. Currently, the options for chemo-
therapy of CAR patients are quite limited and CAR patients
usually do not respond well to such treatments.36 To our
knowledge, the efficacy of Pemetrexed has not been tested in
CAR patients. Our observation that the CAR cases (G5) were
predicted Pemetrexed Rs suggests a possible therapeutic
benefit of Pemetrexed therapy in such cases.
Validation of the Predicted Pemetrexed
Responsiveness Signature
The role of TYMS expression in the efficacy of Pem-
etrexed therapy has been established by several stud-
ies.6,9,16,24 However, TYMS expression alone was not able to
stratify NSCLC cell lines with respect to Pemetrexed sensi-
tivity, and approximately 57% of Pemetrexed-sensitive can-
cer cell lines displayed high TYMS expression (60th per-
centile, n 184, GSE8332). Furthermore, a large variation in
TYMS expression was observed among LCNEC and CAR
primary tumors, which are sensitive to Pemetrexed.37 We
stratified NSCLC patients into different groups by a multi-
gene signature, and this gene signature accurately predicted
Pemetrexed response of the NSCLC cell lines. Because of
several factors, including the lack of availability of suitable
tumor material from Pemetrexed-treated patients to perform
microarray analysis, especially from patients treated with
Pemetrexed as a single agent, our study does not include
retrospective or prospective validation in NSCLC patients.
Our cohort recruited only operated patients who were not
treated with Pemetrexed. Furthermore, Pemetrexed is ap-
proved as second-line treatment of NSCLC or first-line treat-
ment in combination with platinum agents. This precludes
assessment of the impact of Pemetrexed per se. Clinical trials
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where Pemetrexed is administrated as a first-line single agent
for therapy for NSCLC are ongoing and tumor samples from
these patients may become available for future gene expres-
sion profiling experiments.
Gene Expression Profiles May Guide the
Choice of Chemotherapy Regimens
In this study, we show that gene expression profiles
hold promise for classification of patients with respect to
Pemetrexed sensitivity. The identification of the novel G4
classification, and the 25-probe set resistance signature, indi-
cates that rather than by a single gene, Pemetrexed efficacy is
determined by a gene interaction network (Supplemental
Table 5, Supplemental Digital Content 1,
http://links.lww.com/JTO/A168) (Supplemental Fig. 4, Sup-
plemental Digital Content 6, http://links.lww.com/JTO/
A174). This is confirmed by the analysis of resistant and
sensitive NSCLC cell lines.16 A retrospective study tested the
predictive role of TYMS expression and gene polymorphism
for clinical response of colorectal cancer to 5-fluorouracil, a
TYMS inhibitor widely used as anticancer drug. The authors
concluded that TYMS expression is one of multiple determi-
nants of the response to 5-fluorouracil.38 These observations
also support the notion that the use of gene expression
profiles may improve the specificity and sensitivity of pre-
dicting NSCLC NRs to Pemetrexed.
Presently, gene expression profiling of cancer predic-
tive markers in the clinic has not been commonly applied due
to the practical limitations of microarray techniques and
subsequent analytic expertise.39 In contrast, IHC is a standard
assay that is routinely used in clinical pathology. Thus,
immunophenotyping holds promise to classify cancer-intrin-
sic subtypes defined by gene expression profiles while by-
passing the difficulties in implementing microarray technique
in clinical practice. For example, the expression status estrogen
receptor and human epidermal growth factor receptor 2 can be
used to classify breast cancer into four subtypes, which were
originally established by a 50-gene signature.40–43
Potential to Use Surrogate Markers
The assessment of TYMS expression by IHC lacks
sensitivity and is therefore of limited value for the prediction
of Pemetrexed efficacy.14,37 We tested if (a combination of)
routine histological markers (Supplemental Tables 6 and 8,
Supplemental Digital Content 1, http://links.lww.com/JTO/
A168) could be used as an alternative approach to identify
NSCLCs that were predicted to be resistant to Pemetrexed.
Negative TP53 staining assigned the NSCLC in G3 as po-
tentially sensitive to Pemetrexed therapy. The likelihood of
resistance is predicted by high expression of TP53 and
reinforced by concurrent high EGFR expression. Similarly,
tumors in G4 with strong staining for TP53 might be resistant
to Pemetrexed. In contrast, high expression of TP53, EGFR,
or both does not predict resistance for the NSCLCs in G1 or
G6. Positive staining of TTF1 predicts a good response to
Pemetrexed in tumors from G1 or G6, which is in agreement
with a recently published study by Sun et al.44 Furthermore,
the expression of any of three neuroendocrine markers, syn-
aptophysin, NCAM1, and CHGA, in G5 may be predictive of
Pemetrexed sensitivity.
The relationship between TP53 and EGFR expression
with Pemetrexed sensitivity in G3 potentially provides an
instant and practical manner to stratify SCC patients for
Pemetrexed treatment (Supplemental Fig. 8A, Supplemental
Digital Content 10, http://links.lww.com/JTO/A178). High
expression of either TP53 or neuroendocrine markers predicts
Pemetrexed resistance in G4 NSCLCs (Supplemental Fig.
8B, Supplemental Digital Content 10,
http://links.lww.com/JTO/A178), although a few exceptions
were observed in this group. For the other NSCLC subgroups,
a more specific and sensitive marker other than the cooper-
ative use of currently available routine markers is needed.
In conclusion, we suggest a refined classification of
NSCLC subtypes based on gene expression profiles. This
new molecular classification may aid tailored Pemetrexed
therapy for individual NSCLC patients. Although this hy-
pothesis needs to be further validated in clinical settings, our
observations indicate that NSCLC resistant to Pemetrexed
can be identified by molecular means. Furthermore, the ap-
proach we have followed in this study could be generally
applicable to other therapeutic agents and other types of
cancer.
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